Am J Transplant, Volume 20, Suppl 3 Archives - Page 98 of 223 - ATC Abstracts

2020 American Transplant Congress
A Novel Polymer Product, APP-103, Reduces IRI-Induced Damage and Promotes Functional Improvement in Syngeneic Models of Renal Transplantation
K. Minami¹, S. Bae², H. Uehara¹, J. Iske¹, J. Reder³, H. Azuma⁴, A. Weins¹, E. Van Keuren⁵, B. Houser³, A. El-Khal¹, P. Kang², S. Tullius¹
¹Brigham and Women's Hospital, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Celdara Medical, Lebanon, NH, ⁴Osaka Medical College, Osaka, Japan, ⁵Georgetown University, Washington DC, DC
*Purpose: Our data introduce APP-103 as a novel, non-toxic and site-activating therapeutic approach that effectively ameliorates the consequences of ischemia/reperfusion injury in solid organ transplantation.*Methods:…
2020 American Transplant Congress
Hemodialysis (HD) Treatment Associates with Increased Risk of Delayed Graft Function (DGF) after Renal Transplantation (RT) and Augmented Cd4 and Cd8 T Cell Proliferation Compared to Peritoneal Dialysis (PD)
A. Angeletti¹, C. Donadei¹, G. Donati¹, G. Di Certo¹, D. Conte¹, L. Gasperoni¹, E. Pelizzaro¹, C. Guglielmo¹, G. Comai¹, P. Cravedi², G. La Manna¹
¹DIMES, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy, ²DIMES, Icahn School of Medicine at Mount Sinai, New York, NY, US, New York, NY
*Purpose: Delayed graft function (DGF) is a common event after RT that increases the risk of acute rejection and early graft loss. The impact of…
2020 American Transplant Congress
Molecular Phenotypes of Liver Transplant Injury: The INTERLIVER Study
K. S. Madill-Thomsen¹, P. F. Halloran¹, &. the INTERLIVER Study Group²
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²., ., AB, Canada
*Purpose: Liver parenchymal injury phenotypes are difficult to evaluate by histology but could be amenable to molecular assessment. Having developed a Molecular Microscope® Diagnostic System…
2020 American Transplant Congress
Racial Differences in Acceptance of Public Health Service (PHS) Increased Risk Kidneys and Hepatitis C (HCV) Nat Positive Kidneys
K. Atiemo, S. Giusti, A. Paramesh, M. Killackey, H. Jeon
Tulane University, New Orleans, LA
*Purpose: PHS increased risk kidneys and HCV NAT positive kidneys represent a significant proportion of the donor pool however, acceptance demands explicit patient consent that…
2020 American Transplant Congress
Variability in Educational Content about Kidney Paired Donation at 68 National Kidney Registry-Affiliated Centers
A. D. Waterman¹, O. N. Ranasinghe¹, E. H. Wood¹, J. L. Beaumont², S. McGuire³, K. Miller⁴, V. Chipman⁵, J. Sinacore⁶, M. Cooper⁷
¹Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, ²Terasaki Research Institute, Los Angeles, CA, ³UCLA Kidney and Pancreas Transplant Programs, Los Angeles, CA, ⁴UW Health, Madison, WI, ⁵UCSF Medical Center, San Francisco, CA, ⁶National Kidney Registry, Babylon, NY, ⁷Medstar Georgetown Transplant Institute, Washington, DC
*Purpose: Equipping patients and donors with in-depth information about kidney paired donation (KPD) processes, risks, benefits, and protections is necessary for informed decision-making and comfort.…
2020 American Transplant Congress
Introducing the Smartphone App, EL-FIT (Exercise & Liver FITness), to Help Monitor and Prehabilitate Liver Transplant Candidates
A. Duarte-Rojo¹, P. M. Bloomer¹, R. J. Rogers², M. A. Dunn¹, E. B. Tapper³, R. Bataller¹, C. B. Hughes¹, A. A. Ferrando¹, W. R. Kim⁴, J. M. Jakicic²
¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Michigan, Ann Arbor, MI, ⁴Stanford University, Palo Alto, CA
*Purpose: Physical activity is key to liver transplant (LT) prehabilitation, and leveraging technologies to monitor physical performance and to generalize training may be advantageous. EL-FIT…
2020 American Transplant Congress
Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides Difficile Infection among Transplant Recipients
V. Bajrovic¹, T. Johnson², A. Howard², L. Allen³, G. Barber², K. Schwarz², M. Huang³, M. Abidi¹, E. Benamu³, P. Ramanan³, M. Miller⁴
¹Division of Infectious Diseases, University of Colorado, Denver, CO, ²Department of Pharmacy, University of Colorado, Aurora, CO, ³Division of Infectious Diseases, University of Colorado, Aurora, CO, ⁴Department of Pharmacy, University of Colorado, Denver, CO
*Purpose: Clostridioides difficile is an urgent health threat associated with significant morbidity and mortality. Recipients of solid organ (SOT) and hematopoietic-cell transplantations (HCT) are at…
2020 American Transplant Congress
Divergent Molecular Pathways Underlie the Evolution of Allograft Fibrosis in Two Mouse Models of Chronic Lung Allograft Dysfunction
T. Watanabe, J. Allen, K. Boonstra, Z. Guan, K. Bei, S. Keshavjee, J. Yeung, T. Martinu, S. Juvet
Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program / University Health Network, Toronto, ON, Canada
*Purpose: Chronic lung allograft dysfunction (CLAD) after lung transplantation (LTx) is potentiated by activation of the innate immune system and occurs in two patterns: diffuse…
2020 American Transplant Congress
Overcoming Ab-Mediated Xenolung Rejection: Beta4Gal is an Important Pre- and Post-Transplant Ab Target, Relevant to Xenograft Injury in Baboons
L. Burdorf¹, Z. Abady¹, B. Cerel¹, K. Petitpas¹, C. Laird², S. Pratts¹, X. Cheng², C. J. Phelps³, W. Eyestone³, D. L. Ayares³, R. N. Pierson III¹, A. M. Azimzadeh¹
¹Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Surgery, University of Maryland, Baltimore, MD, ³Revivicor, Blacksburg, VA
*Purpose: Knock-out (KO) of porcine carbohydrates (CHO), including Gal 1,3αGal, inhibits antibody-mediated xenograft rejection. The β4Gal epitope was discovered using serum from xenograft-sensitized baboons, but…
2020 American Transplant Congress
Belatacept-Based, Calcineurin Inhibitor and Corticosteroid Free Immunosuppression: Differential Outcomes Based on Recipient Age
N. Wilson¹, A. R. Shields², D. Kaufman³, A. Wiseman⁴, A. L. Christianson¹, S. Tremblay¹, J. P. Leone⁵, A. J. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Wisconsin, Madison, WI, ⁴U Colorado, Denver, CO, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷U Illinois Chicago, Chicago, IL
*Purpose: Age-based disparities have been described in calcineurin inhibitor (CNI)-based immunosuppression regimens, but are not well-described for belatacept (BELA)-based regimens. This study analyzed the effect…